Pemetrexed is a Small Molecule owned by Eagle Pharmaceuticals, and is involved in 1 clinical trial, which is ongoing.

Pemetrexed is an antimetabolite. It inhibits three enzymes involved in the folate pathway which are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase involved in both pyrimidine and purine synthesis. It enters the cells via the reduced folate carrier binds to folate receptor-alpha with a high affinity. Intracellularly, it is polyglutamated to the active pentaglutamide by a reaction catalyzed by enzyme folylpolyglutamate synthase. The increased cellular retention of polyglutamated pemetrexed forms inhibits thymidylate synthase and other enzymes which are necessary for DNA synthesis. By blocking these folate enzymes the drug candidate prevents cancer cells to produce DNA and RNA and thus stops the growth of cancer cells.

The revenue for Pemetrexed is expected to reach a total of $215m through 2028. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pemetrexed NPV Report.

Pemetrexed is currently owned by Eagle Pharmaceuticals.

Pemetrexed Overview

Pemetrexed (Pemfexy / EP-5101) is an antifolate antineoplastic agent. It is formulated as injectable powder for solution for intravenous route of administration. It is indicated for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin.

Eagle Pharmaceuticals Overview

Eagle Pharmaceuticals (Eagle), is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EGL-5385-C-1701 (fulvestrant) and Vasopressin injection for blood pressure. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.

The company reported revenues of (US Dollars) US$171.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 8.7% over FY2020. In FY2021, the company’s operating margin was 1.6%, compared to an operating margin of 17.5% in FY2020. The net loss of the company was US$8.6 million in FY2021, compared to a net profit of US$12 million in FY2020. The company reported revenues of US$65.9 million for the third quarter ended September 2022, a decrease of 11.1% over the previous quarter.

Quick View – Pemetrexed

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Pemetrexed
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.